Editas Medicine Stock News

In last trading session, Editas Medicine Inc. (NASDAQ:EDIT) saw 1.04 million shares changing hands with its beta currently measuring 1.97. Company’s recent per share price level of $30.41 trading at -$2.25 or -6.89% at ring of the bell on the day assigns it a market valuation of $2.13B. That closing price of EDIT’s stock is … Editas Medicine Inc. (NASDAQ:EDIT) Is 3.49% Above Its 52-Week Low, But How Long Can It Continue? Read More »

Editas Medicine, Inc.'s (EDIT) Management Presents at 4th Annual Evercore ISI HealthCONx Conference (Transcript)

Editas Medicine, Inc. (NASDAQ:EDIT) has been given an average recommendation of Hold by the seventeen research firms that are covering the company, Marketbeat reports. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and nine have assigned a buy rating to the company. The average 12-month price []

Cubist Systematic Strategies LLC reduced its stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT) by 85.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,625 shares of the companys stock after selling 61,010 shares during the quarter. Cubist Systematic Strategies LLCs holdings []

AQR Capital Management LLC lessened its holdings in Editas Medicine, Inc. (NASDAQ:EDIT) by 30.5% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 16,239 shares of the companys stock after selling 7,131 shares during the quarter. AQR Capital Management LLCs holdings in Editas Medicine were []

AQR Capital Management LLC trimmed its holdings in shares of Editas Medicine, Inc. (NASDAQ:EDIT) by 30.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,239 shares of the companys stock after selling 7,131 shares during the period. AQR Capital Management LLCs []

Amalgamated Bank grew its stake in Editas Medicine, Inc. (NASDAQ:EDIT) by 35.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,915 shares of the companys stock after purchasing an additional 3,411 shares during the quarter. Amalgamated Banks holdings in Editas Medicine []

Metropolitan Life Insurance Co NY grew its stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT) by 106,883.3% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 19,257 shares of the companys stock after buying an additional 19,239 shares during the period. Metropolitan Life Insurance Co []

Equities analysts expect Editas Medicine, Inc. (NASDAQ:EDIT) to post earnings of ($0.82) per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for Editas Medicines earnings, with the lowest EPS estimate coming in at ($1.16) and the highest estimate coming in at ($0.65). Editas Medicine posted earnings of []

The gene-editing biotech company provided its Q3 update.

Editas (EDIT) delivered earnings and revenue surprises of 33.72% and 5.93%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

EDIT-301 preclinical data support differentiated approach to develop a transformative medicine for people living with transfusion-dependent beta thalassemia

EDIT announced data from BRILLIANCE in late September.

On Editas' (EDIT) third-quarter earnings call, investor focus will likely be on the company's progress with the development of its lead pipeline candidate, EDIT-101.